Original Research
Published on 26 Nov 2025
Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial
in Drugs Outcomes Research and Policies
- 1,074 views